Star’s Electra spinout turning SIRP proteins into depletion handles
The first in a series of spinouts from Star targeting biology shared by multiple diseases, Electra is leveraging insights into the SIRP protein family to stop pathogenic myeloid and T cell activity via a clinical-stage lead program, with a series of preclinical assets behind it. Electra Therapeutics Inc. and its parent company Star Therapeutics both emerged […]
